Dawson James – Can-Fite (CANF) – Hints of Efficacy Continue in HCC as Namodenson Prepares to Go Pivotal in the US and EU

Dawson James – Can-Fite (CANF): Two Patients Alive at Four years – Let’s Go Pivotal

Can-Fite announced new data from the Phase 2 advanced liver cancer study, including overall survival of nearly four years in two patients who are under namodenoson treatment. We are looking for a stream of regulatory events to unfold in 2021; these include the COMFORT trial (Piclidenoson) in psoriasis, a Phase2b study in NASH/NAFLD, and a pivotal liver cancer study (US & EU), both with Namodenoson.

Click Here for the Complete Report: https://files.constantcontact.com/fdcb5758701/e6d71fa8-66fe-408b-a7ed-5d73ed79cfce.pdf

Please visit our website at www.DawsonJames.com, See our Research on Philosophy, Podcasts & Interviews and sign up to receive all of our research reports on all the companies we cover.